PP
GALT icon

Paloma Partners’s Galectin Therapeutics GALT Stock Holding History

Paloma Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-29,850
Closed -$81K – 1713
2015
Q2 		$81K Buy
+29,850
New +$90K ﹤0.01% 1703

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BCCM
Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's GALT Position: Q3 2015 in Review

Paloma Partners sold out of Galectin Therapeutics (GALT) in Q3 2015, closing a stake of 29,850 shares — an estimated $81K sold.

Paloma Partners first reported a position in GALT in Q2 2015 and held it in 1 quarter. The position peaked at $81K in Q2 2015. 51 funds tracked by Wall St. Rank hold GALT as of Q3 2015.

  • Paloma Partners reported no remaining Galectin Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Paloma Partners sold 29,850 Galectin Therapeutics shares in Q3 2015, an estimated $81K.
  • Paloma Partners first reported a position in Galectin Therapeutics in Q2 2015 and held it in 1 quarter.
  • Paloma Partners's Galectin Therapeutics position peaked at $81K in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2015.

Based on Paloma Partners's 13F filing for Q3 2015, filed 16 Nov 2015.